Auxilium Pharmaceuticals, Inc.
http://www.auxilium.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Auxilium Pharmaceuticals, Inc.
Abbott Eagerly Awaits Damages Won From DexCom Patent Suit
Abbott’s trial win for patent infringement by DexCom’s CGM systems still doesn’t have information on damages awarded due a hung jury.
Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results
The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
JPM Day 1: Abbott Riding In Tandem With Libre 2 Plus & t:slim X2 News
The two diabetes players announced a new integration between their products.
Company Information
- Other Names / Subsidiaries
-
- Actient Pharmaceuticals LLC
- Slate Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice